A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | R | S | T | U | V | W | X | Z
Articles are indexed by drug names, trade names and disease terms. Bold entries refer to major references.
Key Word / Drug Name |
Issue #: Page # |
A |
|
abametapir | 2:10 |
ABSSSI | 3:10 |
acne | 2:9; 4:9; 5:12 |
actinic keratosis | 1:12; 2:9,12 |
adalimumab | 2:10,11; 6:6,8 |
AGLE-102 | 1:12 |
alpha-adrenergic agonist | 4:3-4 |
Amgevita® | 2:10-11 |
anakinra | 2:9,12 |
ANCA-associated vasculitis | 6:12 |
androgen receptor inhibitor | 2:9 |
anifrolumab | 5:12 |
anti-neutrophil cytoplasmic | |
autoantibody-associated vasculitis | 6:12 |
anti-TNF | 2:1-5,10,11; 6:7-8 |
anti-acne | 2:9 |
antibacterial | 5:12 |
antibiotic | 3:10; 4:3-4 |
anti-cancer | 2:9 |
antifungal | 1:5-10 |
antineoplastic | 2:9; 5:12 |
antiparasitic | 4:3-4 |
antiviral | 4:14 |
apremilast | 6:7 |
Arazlo™ | 5:12 |
atezolizumab | 2:9 |
atopic dermatitis | 1:1-4; 2:9; 4:9-13,14 ; 6:12 |
avacopan | 6:12 |
Avsola™ | 2:11 |
axatilimab | 3:10 |
azelaic acid | 4:3-6 |
B |
|
baby products | 5:4 |
basal cell carcinoma | 2:9,12 |
benzoyl peroxide | 5:12 |
berotralstat | 1:12; 2:10 |
betamethasone | 2:11 |
bimekizumab | 3:1-4 |
binimetinib | 3:10 |
biologics | 2:1-5,9-10; 6:4-10 |
biosimilar | 2:10; 6:6,8 |
BRAF kinase inhibitor | 2:9; 3:10 |
Braftovi® | 3:10 |
brincidofovir | 4:14 |
brodalumab | 6:6,8 |
Bryhali™ | 4:14 |
bullous pemphigoid | 4:14 |
butorphanol | 3:7 |
Bylvay™ | 5:12 |
C |
|
C1 esterase inhibitor | 2:10 |
C5 complement inhibitor | 4:14; 6:12 |
calcipotriene | 2:11 |
cannabinoids | 3:7-8 |
cellulite | 2:9 |
cemiplimab | 2:12 |
ceramide | 4:10-13 |
certolizumab pegol | 2:1-5; 6:6,8 |
Cervarix® | 2:6-8 |
chemical depilatories | 5:7-11 |
chlormethine hydrochloride | 5:12 |
cidofovir | 4:14 |
Cimzia® | 2:1-5; 6:6,8 |
clascoterone | 2:9 |
cleansers | 4:9-13 |
cobimetinib | 2:9 |
collagenase clostridium histolyticum | 2:9 |
condyloma acuminata | 2:6-8 |
contact dermatitis | 4:9-13,14 |
coronavirus disease 2019 | 4:9 |
cortexolone 17α-propionate | 2:9 |
corticosteroid | 1:1-4; 2:11; 4:14; 6:1-3 |
Cosentyx® | 4:14; 6:7-8 |
cosmetics | 5:1-6 |
Cotellic® | 2:9 |
COVID-19 | 4:9-13 |
crisaborole | 1:1-4; 2:9 |
cutaneous T-cell lymphoma (CTCL) | 5:12 |
cutaneous warts | 2:6-8 |
D |
|
decision-making | 6:4-10 |
depilation | 5:7-11 |
dermal fillers | 2:10; 5:12 |
dermatomyositis | 5:12 |
dermatophyte | 1:5-10 |
dicarboxylic acid | 4:3,7 |
difelikefalin | 6:12 |
Duobrii™ | 2:11; 6:1-3 |
dupilumab | 2:9; 3:7 |
Dupixent® | 2:9; 3:7 |
dystrophic epidermolysis bullosa | 1:12 |
E |
|
eczema | 1:1-4; 2:9; 4:9-13,14; 6:12 |
education | 6:4-10 |
efinaconazole | 1:5-10 |
eflornithine hydrochloride | 5:7,8,10,11 |
electrolysis | 5:7-11; 6:10 |
Enbrel® | 6:6,8 |
encapsulated cell therapy | 3:10 |
encorafenib | 3:10 |
epidermodysplasia verruciformis | 2:6-8 |
epilation | 5:7-11 |
epitheloid sarcoma | 2:9 |
erratum | 6:10 |
erythema | 4:1-6 |
etanercept | 6:6,8 |
Eucrisa® | 1:1-4; 2:9 |
F |
|
Fabry disease | 3:10 |
fixed combination therapy | 6:1-3 |
fragrance-free | 5:1-6 |
G |
|
Gardasil® | 2:6-8 |
gene therapy | 1:12 |
genital warts | 2:6-8 |
golimumab | 2:11 |
graft versus host disease (GVHD) | 3:10; 6:12 |
granulomatosis with polyangiitis | 6:12 |
guselkumab | 2:11; 6:7-8 |
H |
|
Haegarda® | 2:10 |
hair dyes | 5:5 |
hair removal | 5:7-11; 6:10 |
halobetasol propionate | 2:11; 4:14; 6:1-3 |
hand eczema | 4:9-13 |
hedgehog pathway inhibitor | 2:9 |
hereditary angioedema | 2:10 |
hidradenitis suppurativa | 2:10,11 |
HPV immunization | 2:6-8 |
Hulio® | 2:10,11 |
human papillomavirus (HPV) | 2:6-8 |
Humira® | 6:7-8 |
hyaluronic acid (HA) filler | 2:10,12; 5:12 |
hypoallergenic | 5:1-6 |
hypoplasminogenemia | 4:14 |
Hyrimoz® | 2:10,11 |
I |
|
Idacio® | 2:10,11 |
IL-12 | 2:11; 6:7-8 |
IL-17 | 3:1-4; 4:14; 6:6-8 |
IL-23 | 2:11; 6:7-8 |
immune globulin intravenous (IVIg) | 5:12 |
infliximab | 2:11; 6:6,8 |
ingenol mebutate | 1:12 |
insect repellent | 5:5 |
intense pulsed light (IPL) | 5:8-10; 6:10 |
interleukin (IL)-1 | 2:9,12 |
irritant contact dermatitis | 4:9-13,14 |
ivermectin | 1:12; 4:3-4 |
ixekizumab | 6:7-8 |
J |
|
Jakafi® | 6:12 |
Janus kinase (JAK) inhibitor | 6:12 |
Jublia® | 1:5-10 |
Juvéderm® Voluma™ XC | 2:10 |
K |
|
Kaposi sarcoma | 2:9 |
keratinocyte carcinomas | 2:6-8 |
Keytruda® | 2:9; 5:12 |
Kimyrsa™ | 3:10 |
Kineret® | 2:9,12 |
Klisyri® | 2:9,12 |
Korsuva™ | 6:12 |
Koselugo® | 2:10 |
KPL-716 | 1:12 |
L |
|
labeling laws | 5:1-6 |
laser therapy | 4:4; 5:7-11; 6:10 |
Ledaga™ | 5:12 |
Libtayo® | 2:11 |
lice | 1:12; 2:10 |
Livmarli™ | 6:12 |
M |
|
maralixibat | 6:12 |
MEK inhibitor | 2:9,10; 6:12 |
Mektovi® | 3:10 |
melanoma | 2:9,12; 3:10 |
microscopic polyangiitis | 6:12 |
microtubule inhibitor | 2:9,12 |
minocycline | 2:11 |
moisturizers | 4:9-13 |
monoclonal antibody | 1:12; 2:10–12; 3:1-4,5-8,10 |
mycosis fungoides | 5:12 |
N |
|
nail disorder | 1:5-10 |
nalbuphine | 3:7 |
naloxone | 3:7 |
naltrexone | 3:7 |
nemolizumab | 3:5-8 |
neurofibromatosis | 2:10; 6:12 |
NFX-179 | 6:12 |
nomacopan | 4:14 |
O |
|
obstetrics | 2:1-5 |
Octagam® | 5:12 |
odevixibat | 5:12 |
Odomzo® | 2:9 |
onychomycosis | 1:5-10 |
opioid receptor modulation | 3:7 |
Opzelura™ | 6:12 |
oritavancin | 3:10 |
Orladeyo™ | 1:12 |
Otezla® | 6:7 |
P |
|
patient education | 6:4-10 |
PD-L1 antibody | 2:9,12 |
PDE4 inhibitor | 1:1-4; 2:9; 6:7 |
pembrolizumab | 2:9; 5:12 |
personal care products | 5:1-6 |
personal protective equipment (PPE) | 4:9 |
phenotype approach (rosacea) | 4:1-6 |
phosphodiesterase-4 inhibitor | 1:1-4; 2:9; 6:7 |
photodynamic therapy | 5:7-11 |
phyma | 4:1-6 |
Picato® | 1:12 |
plasma kallikrein inhibitor | 1:12 |
plasminogen | 4:14 |
plucking | 5:8-9 |
pomalidomide | 2:9 |
Pomalyst® | 2:9 |
pregnancy | 2:1-5 |
programmed death receptor-1 (PD-1) | 2:9,12; 5:12 |
pruritus | 5:12; 6:12 |
psoriasis | 2:1-5,10,11; 3:1-4; 4:14; 6:1-3,4-10 |
psoriatic arthritis | 2:10,11; 4:14 |
prurigo nodularis | 1:12; 3:5-8 |
R |
|
Remicade® | 6:6,8 |
Restylane® Contour™ | 5:12 |
Restylane® Defyne™ | 2:12 |
Restylane® Kysse™ | 2:10 |
retinoid | 4:1-4; 5:12; 6:1-3 |
risankizumab | 6:7-8 |
rosacea | 2:11; 4:1-6 |
ruxolitinib | 6:12 |
Ryplazim® | 4:14 |
S |
|
Saphnelo™ | 5:12 |
secukinumab | 4:14; 6:7-8 |
selumetinib | 2:10 |
sensitive skin | 5:1-6 |
shared decision-making | 6:4-10 |
Siliq® | 6:6,8 |
Simponi® Aria™ | 2:11 |
Sklice® | 1:12 |
Skyrizi® | 6:7-8 |
smallpox | 4:14 |
sonidegib | 2:9 |
squamous cell carcinoma | 2:6-8,9; 5:12 |
Stelara® | 2:11 |
sugaring | 5:8-9 |
sunscreens | 5:2-5 |
systemic lupus erythematosus | 5:12 |
T |
|
Taltz® | 6:7-8 |
Tavneos™ | 6:12 |
tazarotene | 2:11; 5:12; 6:1-3 |
tazemetostat | 2:9 |
Tecentriq® | 2:9 |
telangiectasia | 4:1-6 |
Tembexa® | 4:14 |
threading | 5:8-9 |
tirbanibulin | 2:9,12 |
TNF-alpha | 2:1-5,10,11; 6:6,8 |
topical treatment | 1:1-4; 2:9–12 |
Tremfya® | 2:11; 6:7-8 |
tretinoin | 5:12 |
tumor necrosis factor-alpha | 2:1-5,10,11; 6:6,8 |
Twyneo® | 5:12 |
U |
|
ustekinumab | 2:11; 6:7-8 |
V |
|
vaccines | 2:6-8,12 |
Vaniqa® | 5:7,8,10 |
vemurafenib | 2:9 |
verruca vulgaris | 2:6-8 |
vixarelimab | 1:12 |
W |
|
waxing | 5:8-9 |
Winlevi® | 2:9 |
Wynzora® | 2:11 |
X |
|
Xeglyze™ | 2:10 |
Z |
|
Zelboraf® | 2:9 |
Zilxi™ | 2:11 |